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1. Introduction 
Although the advent of highly active antiretroviral therapy (HAART), including potent 
protease inhibitors (PIs), has profoundly reduced human immunodeficiency virus (HIV) 
mortality and morbidity (Palella et al., 1998; CDC, 2009), these combination regimens are not 
a cure for HIV infection and therapy may be life long. While many patients benefit from 
HAART treatment, others do not benefit or only experience a temporary benefit. There are 
several reasons why treatment fails, with poor patient adherence to HAART a leading 
contributing factor (Ickovics & Meisler, 1997; Paterson, 2000). Thus, assessment of 
medication adherence within AIDS clinical trials is a critical component of the successful 
evaluation of therapy outcomes. Maintaining adherence may be particularly difficult when 
the drug regimen is complex or side-effects are common, as is often the case for current HIV 
therapy especially in highly treatment experienced patients (Ickovics & Meisler, 1997). 
The measurement of adherence remains problematic; a standard definition of optimal 
adherence and completely reliable measures of adherence are lacking. Nevertheless, there 
has been substantial progress in both of these areas in the past few years. First, it appears 
that higher levels of adherence are needed for HIV disease than other diseases to achieve the 
desired therapeutic benefit. Using questionnaires (patient self-reporting and/or face-to-face 
interview) and electronic compliance monitoring caps (Medication Event Monitoring 
System [MEMS]), viral suppression is common with at least 54%–100% mean adherence 
level to antiviral regimens (Bangsberg, 2006). Second, a better appreciation of the value and 
limitations of different adherence measurements has been addressed (Berg & Arnsten, 2006; 
Bova et al., 2005). In AIDS clinical trials, adherence to a medication regimen is currently 
measured by two major methods: by use of questionnaires and by use of MEMS. The MEMS 
is considered an objective adherence measure. It consists of a microprocessor in the cap of a 
medication bottle which records the date and time of bottle opening. The results are 
downloaded to a computer for analysis. Results demonstrate that medication-taking 
patterns are highly variable among patients (Kastrissios et al., 1998) and that they often give 
a more precise measure of adherence than self-report (Arnsten et al., 2001a). However, 
MEMS data are also subject to error and are not widely available in the clinical setting. 
Adherence assessment by self-report is usually evaluated by a patient’s ability to recall their 
medication dosing during a specific time interval. Often self-reported measures tend to 
overestimate HIV medication adherence compared to other methods (Arnsten et al., 2001b, 
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Bangsberg et al. 2000; Levine et al., 2006; Liu et al., 2001). Finally, it is important to note that 
the measurement of viral load levels is of special utility as an indirect measure of adherence 
in HIV therapeutics. It has been argued that this is not a good adherence measure because 
other factors may influence viral load (pharmacokinetics, drug resistance etc.). However, 
there is a tight correlation between viral load and adherence (Haubrich et al., 1999; Paterson 
et al., 2000), but results vary by adherence method and summary adherence statistic (Vrijens 
& Goetghebeur, 1997; Vrijens et al., 2005) . Several recent papers explore the methodological 
and operational issues when evaluating electronic drug monitoring adherence on viral load 
(Arnsten et al., 2001b; Fennie et al., 2006; Fletcher et al., 2005; Llabre et al., 2006; Liu et al. , 
2006; Liu et al. , 2007; Pearson et al. , 2007; Vrijens et al., 2005). Most importantly, a favorable 
change in viral load is the desired therapeutic outcome of adherence to HAART.  
In this paper, we propose using a viral dynamic model with consideration of long-term 
medication adherence and drug susceptibility to explore the relationship between adherence 
to two protease inhibitors, as part of an HAART regimen, and long-term virologic response. 
In particular, we will use different adherence measures from an AIDS clinical trial study--
ACTG398 (Hammer et al., 2002) and compare their performance for predicting virologic 
response. The dynamic modeling approach (Huang et al., 2006; 2010) allows us to 
appropriately capture the sophisticated nonlinear relationships and interactions among 
important factors and virologic response. The complete HIV-1 RNA (viral load) trajectories 
serve as the virologic response index, which is more informative and sensitive to clinical and 
drug factors. Thus, this method is more powerful to detect the effect of a clinical or drug 
factor on the response. Using a Bayesian method (Huang et al., 2006), we fit a long-term 
viral dynamic model to data from the AIDS clinical trial study to explore the association 
between adherence and viral load in HIV-infected patients with adjustment of the potential 
confounding factor, drug susceptibility. In this study, we employed the proposed 
mechanism-based dynamic model to assess how to efficiently use the adherence data based 
on questionnaires and the MEMS to predict virologic response. In particular, we intend to 
address the questions (i) how to summarize the MEMS adherence data for efficient 
prediction of the virologic response, and (ii) which adherence assessment method, 
questionnaire or MEMS, is more efficient in predicting the virologic response after 
accounting for the potential confounding factor, drug resistance. We expect that viral 
dynamic modeling not only provides a powerful tool to evaluate the effect of adherence on 
long-term virologic responses, but also can be used to predict antiviral responses for various 
scenarios that may help with understanding the role of different adherence measure 
statistics in antiviral activities and assist clinicians in treatment decisions.  
2. Materials 
In this section, we describe the subject population to be studied and observed data to be 
used in this research. These measurements include RNA viral load, phenotypic drug 
sensitivity and medication adherence. We also discuss how to evaluate assessment interval 
lengths and time frames (delay effect of timing) for the MEMS adherence data. 
2.1 Subject population 
The subject sample in our analysis was drawn from the AIDS Clinical Trials Group (ACTG) 
398 study (Hammer et al., 2002), a randomized, double-blind, placebo-controlled phase II 
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study of amprenavir (APV) as part of several dual protease inhibitor (PI) regimens in 
subjects with HIV infection in whom initial PI therapy had failed. One of objectives of the 
ACTG 398 study was to evaluate the genotypic and phenotypic resistance profiles that 
emerge on treatment and their relationship to the plasma HIV-1 RNA and CD4 cell count 
responses, and to determine the relationship between drug exposure measured from 
combined PK and adherence data to the degree and duration of viral response. Subjects in 
all arms received APV (1200 mg twice a day [q12h]), efavirenz (EFV, 600 mg once a day 
[qd]), abacavir (300 mg q12h) and adefovir dipivoxil (60 mg qd). A total of 481 subjects were 
randomized to four treatment arms and received a second PI or placebo: Arm A (n=116) 
saquinavir (1600 mg q12h); Arm B (n=69) indinavir (1200 mg q12h); Arm C (n=139) 
nelfinavir (NFV, 1250 mg q12h); and Arm D (n=157) received a placebo matched for one of 
these three PIs. Assignment of subjects to treatment arms depended on past PI exposure in 
the arm. Subjects were scheduled for follow-up visits at study (day 0); at weeks 2, 4, 8, 16 
and every 8 weeks thereafter until week 72; and at the time of confirmed virologic failure. 
More detailed descriptions of this study and study results are given by Hammer et al. (2002) 
and Pfister et al. (2003). Because phenotype sensitivity testing was performed only on a 
subset of randomly selected subjects, the number of subjects available for our analysis was 
greatly reduced. We chose to consider only the subjects within Arm C for our analysis 
because this arm afforded the greatest number of subjects (n=31) with phenotypic drug 
susceptibility data on the two PIs (APV and NFV) and had available adherence data, as 
required for our model. Among these 31 subjects, 13 had phenotypic drug susceptibility 
data at the time of protocol-defined virologic failure. 
2.2 Observed measurements  
RNA viral load: RNA viral load was measured in copies/mL at study weeks 0, 2, 4, 8 and 
every 8 weeks thereafter until week 72 by the ultrasensitive reverse transcriptase-
polymerase chain reaction HIV-1 RNA assay. Only measurements taken while on protocol-
defined treatment were used in the analysis. All viral load values were log (base 10) 
transformed. Although, the lower limit of assay quantification was 200 copies/mL, when 
lower values (<200 copies/mL) were detected, these values were used in the analysis. The 
exact day of viral load measurement (not predefined study week) was used to compute 
study day in our analysis. 
Medication adherence: Medication adherence was measured by two methods-- by the use 
of questionnaires and by the use of electronic monitoring caps. Subjects completed an 
adherence questionnaire (AACTG study 398 questionnaire QL0702) at study weeks 4, 8, 12, 
16, and every 8 weeks thereafter. The questionnaire was completed by the study participant 
and/or by a face-to-face interview with study personnel. The subject was asked to specify 
the number of prescribed doses of each drug that he or she had failed to take on each of the 
preceding 4 days. Questionnaire adherence rates for APV and NFV were determined at each 
visit as the number of prescribed doses taken divided by the number prescribed doses 
during the preceding 4 day interval. For electronically monitored adherence, an MEMS cap 
(Medication Event Monitoring Systems, Aprex Corp., Menlo CA) was used to monitor APV 
and EFV compliance only. Subjects were asked to bring their medication bottles and caps to 
the clinic at each study visit (weeks 2, 4, 8, 12, 16, and every 8 weeks thereafter), where cap 
data were downloaded to computer files and stored for later analysis. Since APV was 
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prescribed twice daily, a prescribed AM and PM dosing period was defined for each subject. 
If a subject opened the bottle at least once during a dosing period, then the subject was 
recorded as having a positive event (x=1), otherwise (x=0). The MEMS adherence rate for 
APV was determined as the sum of positive dosing events divided by the sum of prescribed 
dosing events during the specified time interval. A positive dosing event assumes a 
presumptive dose. If the MEMS cap was recorded as not in use, the MEMS dosing event was 
set to missing. In our analysis, we assumed that NFV had the same MEMS adherence rate as 
APV. 
 
  Adherence assessment definition  
Case 
MEMS adherence 
interval notation 
Interval 
length 
Time frame length 
(weeks to RNA 
measurement) 
Example for day 56, 
adherence computed 
over 
1 M visit time 0 Days 28 – 55 
2 M0.1 1 week 0 Days 49 - 55 
3 M0.2 2 weeks 0 Days 42 – 55 
4 M0.3 3 weeks 0 Days 35 – 55 
5 M1.1 1 week 1 week Days 43 – 49 
6 M1.2 2 weeks 1 week Days 36 – 49 
7 M1.3 3 weeks 1 week Days 29 – 49 
8 M2.1 1 week 2 weeks Days 36 – 42 
9 M2.2 2 weeks 2 weeks Days 29 – 42 
10 M2.3 3 weeks 2 weeks Days 22 – 42 
11 M3.1 1 week 3 weeks Days 29 – 35 
12 M3.2 2 weeks 3 weeks Days 22 – 35 
13 M3.3 3 weeks 3 weeks Days 15 - 35 
Table 1. Summary of the MEMS assessment interval notation and definitions 
To determine the best summary metric of the MEMS adherence rate, we evaluated different 
assessment interval lengths (averaging adherence dosing events over 1, 2, or 3 week 
intervals) and different assessment time frames (fixing the assessment interval times to end 
either immediately or 1, 2 or 3 weeks prior to the next measured viral load). Table 1 
summarizes the MEMS assessment interval notation and definitions for the 13 models. As 
an example, M2.2 in Table 1 denotes an MEMS adherence interval length of 2 weeks fixed to 
end 2 weeks prior to the next viral load measurement; for instance, the MEMS adherence 
rate for a subject at study week 8 (day 56) was calculated as the number of nominal dosing 
events divided by the number of prescribed dosing events over study days 29 - 42. The case 
M serves as a reference and averages all the available MEMS data between viral load 
measurements. 
Phenotypic drug susceptibility: Retrospectively, 200 subjects were randomly selected from 
the entire ACTG 398 study population for phenotypic sensitivity testing. Of these 139 
subjects were tested at baseline based on receiving study treatment for at least 8 weeks and 
having an available sample. Among these subjects, 59 subjects experienced protocol-defined 
virologic failure and phenotypic sensitivity testing was performed at the time of failure 
(Hammer et al., 2002). Phenotypic drug susceptibility was determined by a recombinant 
virus assay (PhenoSense, ViroLogic, Inc) and values were expressed as the 50% inhibitory 
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concentration (IC50) (Molla et al., 1996). All 31 subjects used in our analysis had baseline 
APV and NFV IC50 values, of which 13 subjects had follow-up APV and NFV IC50 values at 
the time of virologic failure. 
3. Mathematical models and statistical methods  
We fit the dynamic model to the viral load data from 31 subjects with the following 
considerations. (i) In the model we incorporate the two clinical factors, drug adherence 
(questionnaire or MEMS) and drug susceptibility (phenotype IC50 values), into a function of 
treatment efficacy. (ii) We only consider the PI drug effects in the drug efficacy model 
because the effect of RTI drugs is considered less important compared to the PI drugs and 
would require a different efficacy model. (iii) We assume that NFV has the same compliance 
rate as determined for APV by the MEMS method. Details of the mathematical models and 
statistical methods are described in Huang et al. (2006) and Wu et al. (2005). For 
completeness, a brief summary of the models and methods is given as follows.  
3.1 Drug resistance model 
As Molla et al. (1996) suggested, the phenotype marker, median inhibitory concentration 
(IC50), can be used to quantify agent-specific drug susceptibility. We use the following 
model to approximate the within-host changes over time in IC50 (Huang et al., 2003; Huang 
et al., 2006; Wu et al., 2005). 
 
0
0
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for 0
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for
r
r
r
r r
I I
I t t t
tIC t
I t t
       
                   (1) 
Where 0I  and rI  are respective values of 50( )IC t  at baseline and time point rt  at which 
resistant mutations dominate. In our study, rt  is the time of virologic failure. For subjects 
without a failure time IC50, baseline IC50 was held constant over time. 
3.2 Medication adherence model  
Poor adherence to a treatment regimen is one of the major causes of treatment failure. 
(Ickovics abd Meisler, 1997). The following model is used to represent adherence for a time 
interval 1k kT t T   ,  
 
1
1
1 if all doses are taken in ( ]
( )
if 100 doses are taken in ( ]
k k
k k k k
T T
A t
R R % T T


    
                (2) 
where 0 1kR  , with kR  indicating the adherence rate computed for each assessment 
interval ( 1k kT T  ] based on the questionnaire or MEMS data; kT  denotes the adherence 
assessment time at the kth clinical visit. 
3.3 Drug efficacy model 
In most viral dynamic studies, investigators assumed that either drug efficacy was constant 
over treatment time (Perelson and Nelson, 1999; Wu and Ding, 1999; Ding and Wu, 2001) or 
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antiviral regimens had perfect effect in blocking viral replication (Ho et al., 1995; Perelson et 
al., 1996, 1997). However, the drug efficacy may change as concentrations of antiretroviral 
drugs and other factors (e.g. drug resistance) vary during treatment (Dixit et al., 2004). We 
employ the following modified maxE  model (Sheiner, 1985) to represent the time-varying 
drug efficacy ( see Wu et al. (2005) for more discussion about the drug effect maxE  model) for 
two antiretroviral agents within a class (for example, the two PI drugs APV and NFV),  
 
1 2
1 50 2 50
1 2
1 50 2 50
( ) ( ) ( ) ( )
( )
( ) ( ) ( ) ( )
A t IC t A t IC t
t
A t IC t A t IC t
 
                               (3) 
where 50( )
kIC t  ( 1 2)k    are median inhibitory concentration change over time for the two 
agents; ( )kA t  ( 1 2)k    are adherence profiles of the two drugs measured by questionnaire or 
the MEMS method. Parameter   can be regarded as a conversion factor between in vitro and 
in vivo IC50 s and will be estimated from the data. Note that ( )t  ranges from 0 to 1. 
3.4 Antiviral response model 
We consider a simplified HIV dynamic model with antiviral treatment as follows. (Huang et 
al., 2006; Wu et al., 2005). 
 
[1 ( )]
[1 ( )]
T
d
T d T t kTV
dt
d
T t kTV T
dt
d
V N T cV
dt
 
 

 

    
   
  
                             (4) 
where the three differential equations represent three compartments: target uninfected cells 
( T ), infected cells ( T ) and free virions (V ). Parameter   represents the rate at which new 
T cells are generated from sources within the body, such as the thymus, Td  is the death rate 
of T cells, k  is the infection rate without treatment,   is the death rate of infected cells, N  
is the number of new virions produced from each of infected cell during its life-time, and c  
is the clearance rate of free virions. The time-varying parameter ( )t  is the antiviral drug 
efficacy at treatment time t . 
3.5 Bayesian modeling approach 
Although a number of studies investigated various statistical methods, including Bayesian 
approaches, of fitting viral dynamic models to predicting virologic responses using short-
term viral load data (Wu and Ding, 1999; Ho et al., 1995; Perelson et al., 1996, 1997; Wu et al., 
1999; Notermans et al., 1998; Markowitz et al., 2003; Han et al., 2002), little work has been 
undertaken to investigate long-term virologic responses. In this paper, we used a 
hierarchical Bayesian modeling approach (Huang et al., 2006) to estimate the dynamic 
parameters.  
We denote the number of subjects by n and the number of measurements on the ith 
subject by im . For notational convenience, let (ln ln ln ln ln ln ln )
T
Tc d N k          , 
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{ 1 }i i n      , (ln ln ln ln ln ln ln )Ti i i i i Ti i ic d N k          , { } { }li l i     and 
{ 1 1 }ij iy i n j m        Y   . Let 10( ) log ( ( ))i iij j i jf t V t    , where ( )ii jV t   denotes the 
numerical solution of the differential equations (4) for the ith subject at time jt . Let ( )ijy t  
and ( )i je t  denote the repeated measurements of common logarithmic viral load and a 
measurement error with mean zero, respectively. The Bayesian nonlinear mixed-effects 
model can be written as the following three stages (Davidian and Giltinan, 1995; Huang et 
al., 2006).  
Stage 1. Within-subject variation:  
 2 2( ) (0 )
ii ii i i i m
N       y f e e I          (5) 
where 1 1( ( ) ( ))i i
T
i i im my t y t  y  , 1 1( ) ( ( ) ( ))i i Ti i ii i im mf t f t      f  , 1( ( ) ( ))i Ti i i me t e t  e  .  
Stage 2. Between-subject variation:  
 (0 )i i i N      b b                               (6) 
Stage 3. Hyperprior distributions:  
 2 1( ) ( ) ( )Ga a b N Wi                               (7) 
 
where the mutually independent Gamma ( Ga ), Normal ( N ) and Wishart ( Wi ) prior 
distributions are chosen to facilitate computations (Davidian and Giltinan, 1995). The hyper-
parameters a b     and   were determined from previous studies and the literature 
(Perelson and Nelson, 1999; Ho et al., 1995; Perelson et al., 1996, 1997; Nowak and May, 
2000). See Huang et al. (2006) for a detailed discussion of the Bayesian modeling approach, 
including the choice of the hyper-parameters, and the implementation of the Markov chain 
Monte Carlo (MCMC) procedures (Gamerman, 1997; Wakefield, 1996). 
4. Results  
4.1 Subject characteristics 
Of the 31 subjects used in our analysis, the mean age was 40 years (SD=7); 94% were men; 
and 65% were white, 23% black, 10% Hispanic and 3% Asian. At baseline, 58% had prior 
nonnucleoside reverse transcriptase inhibitor (NNRTI) experience. Median baseline CD4 cell 
count was 196 cells/uL (interquartile range=120-308 cells/uL) and median baseline viral 
load was 38,019 copies/mL (interquartile range=19,498-181,970 copies/mL). Median time to 
the last viral load measurement while on protocol-defined treatment was 227 days 
(interquartile range=168-321 days). Median baseline IC50 values were 21.2 ng/mL and 38.9 
ng/mL for APV and NFV, respectively. Among the 13 subjects with IC50 values at failure 
time, the median time to virologic failure was 157 days. Overall mean questionnaire 
adherence rate was 0.95 and 0.96 respectively for APV and NFV and the MEMS adherence 
rate for APV was 0.80. Fig. 1 shows the viral load (log10 transformed) and adherence rates 
over time based on questionnaire data for APV and NFV drugs and APV MEMS data (13 
summary metrics) for one representative subject. 
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Fig. 1. The trajectories of viral load on log10 scale (solid curves) and adherence rates 
(stairsteps) over time based on questionnaire data for APV and NFV drugs (upper-left 
panel) and MEMS data summarized by the 13 models for APV drug (other panels) for one 
subject 
We fit the viral dynamic model to the data from 31 subjects described previously using the 
proposed Bayesian approach. We incorporated the two clinical factors, drug adherence 
(questionnaire or MEMS) and drug susceptibility (phenotype IC50 values), into a function of 
treatment efficacy (3). For model fitting and the purpose of comparisons, we set up a control 
model as the one without using any adherence and drug susceptibility data which 
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corresponds to setting A(t) and IC50(t) to be 1 in Eq. (3), i.e., ( ) 2 ( 2)t    . Other 14 models 
are specified based on the combination of drug susceptibility (IC50) data and 14 different 
adherence summary metrics (1 questionnaire and 13 MEMS summary metrics listed in Table 
1). Note that the abbreviation IM2.2, for example, denotes the model incorporating the data of 
drug resistance (I) and MEMS adherence rate (M2.2) summarized as an interval length of 2 
weeks fixed to end 2 weeks prior to the next viral load measurement. For example, the MEMS 
adherence rate for a subject at study week 8 (day 56) was calculated over a 14 day interval 
from study days 29-42 and this value was used to represent adherence from the previous 
study visit to the study visit at day 56 for modeling fitting. 
4.2 Model fitting 
In order to assess how adherence rates, determined from 14 different scenarios, interact with 
drug susceptibility to contribute to virologic response, we fitted the models to all 14 
scenarios as well as the control model and compared the fitting results. We found that, 
overall, the model with adherence rate determined from MEMS dosing events averaged 
over a 2 week assessment interval either 1 week prior to a viral load measurement (IM1.2) or 
2 weeks prior to a viral load measurement (IM2.2) provided the best fits to the observed 
data, compared to the other 13 models for most subjects; the control model, lacking factors 
for subject-specific drug adherence and susceptibility, failed to fit viral load rebounds and  
 
Fig. 2. The estimated viral trajectory for three representative subjects from the model fitting: 
(i) Control model (solid curves), (ii) IM1.2 (dotted curves) and (iii) IM2.2 (dashed curves). 
The observed values are indicated by circles. 
fluctuations and provided the worst fitting results for the majority of subjects. For the 
purpose of illustration, the model fitting curves for three representative subjects from the 
control model (solid curves), the IM1.2 model (dotted curves), and the IM2.2 model (dashed 
curves) are displayed in Fig. 2. 
4.3 Individual dynamics parameter estimates 
Table 2 presents the results of estimated dynamic parameters for individual subjects and the 
sample summary statistics (minimum, median, mean, maximum, standard deviation (SD) 
and coefficient of variation (CV) for the model IM2.2 that provided the best fit to the 
observed data. We can see from Table 2 a relatively large between-subject variation in the  
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Subject i  ci δi λi dTi Ni ki x 104 
1 0.002 3.144 0.105 68.830 0.041 126.353 2.083 
2 0.002 3.366 0.203 193.493 0.021 763.481 0.800 
3 0.002 3.065 0.228 103.261 0.051 516.932 1.363 
4 0.001 3.963 0.294 67.549 0.110 709.988 0.738 
5 0.002 2.499 1.238 171.962 0.142 9384.339 0.868 
6 0.002 3.219 0.224 108.737 0.056 495.182 1.526 
7 0.002 3.631 0.078 111.508 0.017 109.594 1.549 
8 0.001 4.103 0.157 73.195 0.050 354.894 1.124 
9 0.002 2.286 0.809 177.204 0.097 4070.423 1.112 
10 0.002 2.620 1.058 208.394 0.091 6031.472 1.033 
11 0.002 3.213 0.219 83.127 0.058 479.131 1.316 
12 0.002 2.804 0.315 96.976 0.071 806.579 1.622 
13 0.001 3.705 0.164 88.307 0.056 581.903 0.727 
14 0.002 2.877 0.132 130.303 0.026 341.015 1.347 
15 0.003 2.316 0.434 207.091 0.043 2197.731 1.064 
16 0.003 1.753 0.924 160.891 0.120 4224.349 1.867 
17 0.001 4.041 0.211 127.465 0.023 765.045 0.692 
18 0.002 3.367 0.216 85.716 0.051 508.451 1.148 
19 0.002 3.955 0.114 74.292 0.033 164.046 1.498 
20 0.001 3.938 0.116 117.911 0.023 356.109 0.801 
21 0.001 2.887 0.314 306.351 0.019 1636.315 0.486 
22 0.003 2.003 0.569 100.966 0.067 1186.222 0.654 
23 0.001 4.273 0.260 43.015 0.136 474.269 1.258 
24 0.001 3.506 0.131 157.873 0.028 643.514 0.847 
25 0.002 2.277 0.839 174.871 0.105 4912.339 1.189 
26 0.001 3.847 0.340 54.983 0.135 714.569 1.116 
27 0.003 2.730 0.218 103.326 0.042 411.427 1.690 
28 0.002 3.510 0.073 133.204 0.015 106.627 1.366 
29 0.002 3.751 0.186 108.477 0.026 435.276 1.111 
30 0.002 3.760 0.162 96.575 0.031 354.927 1.192 
31 0.002 3.415 0.144 112.288 0.034 392.298 1.140 
Min 0.001 1.753 0.073 43.015 0.015 106.627 0.486 
Med 0.002 3.367 0.218 108.737 0.050 516.932 1.140 
Max 0.003 4.273 1.238 306.351 0.142 9384.339 2.083 
Mean 0.0017 3.285 0.328 124.134 0.059 1427.574 1.172 
SD 0.0006 0.647 0.305 55.726 0.039 2118.271 0.373 
CV (%) 33.037 19.686 93.066 44.892 66.245 148.383 31.801 
Table 2. The estimated dynamic parameters from the IM2.2 model for individual subjects, 
where Min, Med, Max, SD and CV=SD/Mean denote the minimum, median, maximum, 
standard deviation and coefficient of variation, respectively. 
www.intechopen.com
 
Modeling Virologic Response in HIV-1 Infected Patients to Assess Medication Adherence 
 
61 
seven viral dynamic parameters was observed (CV ranges from 20% to 148%) among the 31 
subjects. Generally speaking, the virologically successful subjects (maintaining plasma HIV-
1 RNA levels of less than 200 copies/mL) have higher clearance rates of free virions (c), but 
smaller efficacy parameter estimates (), and lower death rates of infected cells (); these 
results show the similar patterns to those displayed in Figure 4 studied by Wu et al. (2005) 
The individual parameter estimates from both the IM2.2 and IM1.2 models are significantly 
correlated for all seven parameters, while the individual parameter estimates for the control 
model appear significantly different from those for the model IM2.2 for most of the seven 
parameters (data not shown here). 
4.4 Effects of adherence rate determined by questionnaire vs. MEMS data 
In order to assess how different adherence rates measured by questionnaires and MEMS 
contribute to the virologic response, we compared the fitting results of models with all 14 
adherence scenarios and the control model. The mean of the sum of the squared deviations 
(SSD) was used to assess model fit and the SSD was calculated by 2
1
ˆ( )i
m
ij ijj
yy   for each 
subject, where ijy  and ˆ ijy  are the observed and predicted values, respectively. The mean 
SSDs are plotted for all the models in Fig. 3, with the best fitting models having a smaller 
mean SSD, and sign test p-values from pairwise comparisons are reported in Table 3. 
 
Fig. 3. Comparison of mean of SSDs for models from the 14 different determinants of 
adherence with drug resistance and the control model. The three horizontal lines represent 
mean of the SSDs for control, IA and IM models, respectively. 
4.5 What MEMS assessment interval length is best? 
The pattern in Fig. 3 shows that when the time frame for MEMS assessment is fixed, models 
with a 2 week MEMS assessment interval length generally outperform models with an 
assessment interval length of 1 or 3 weeks.  
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Model Control IA IM IM0.1 IM0.2 IM0.3 IM1.1 IM1.2 IM1.3 IM2.1 IM2.2 IM2.3 IM3.1 IM3.2 
IA <0.001              
IM  <0.001 0.106             
IM0.1 0.106 0.007 0.002            
IM0.2 0.019 0.209 0.007 0.020           
IM0.3 0.048 0.048 0.020 0.106 0.369          
IM1.1 0.001 0.590 0.020 0.106 0.209 0.858         
IM1.2  <0.001 0.048 0.029 0.002 0.007 0.007 0.007        
IM1.3 0.001 0.858 0.858 0.048 0.048 0.048 0.209 0.048       
IM2.1 <0.001 0.106 0.209 0.020 0.007 0.048 0.048 0.048 0.209      
IM2.2 <0.001 0.007 0.020 <0.001 0.001 <0.001 0.048 0.590 0.048 0.020     
IM2.3 <0.001 0.369 0.209 0.011 0.002 0.002 0.209 0.106 0.858 0.590 0.048    
IM3.1 0.106 0.007 <0.001 0.369 0.590 0.048 0.007 <0.001 0.007 0.001 0.002 0.002   
IM3.2 0.106 0.209 0.002 0.858 0.858 0.007 0.007 0.001 0.002 0.007 0.007 0.002 0.048  
IM3.3 0.001 0.858 0.020 0.048 0.020 0.369 0.209 0.007 0.369 0.369 0.001 0.020 0.002 0.020 
MSSD 11.30 6.06 5.27 9.77 7.77 8.27 8.09 4.75 6.00 6.73 4.11 5.16 11.12 11.56 
Table 3. Pairwise comparisons of sum of squared deviations (SSD) from individual subjects 
for 15 models. The p-values were obtained using the sign test and MSSD is the mean of SSD  
4.6 What MEMS assessment time frame (delay effect of timing) is best? 
As seen in Fig. 3, regardless of the assessment interval length, models which assess 
compliance 2 weeks prior to viral load generally outperform models which assess 
compliance immediately before viral load, 1 week before or 3 weeks before viral load 
measurement. Overall, the model with a MEMS assessment interval length of 2 weeks 
measured from 4 to 2 weeks prior to viral load measurement (IM2.2) was significantly a 
better predicator of viral load over time than any other models, with the exception of the 
IM1.2 model.  
From Table 3, the means and standard deviations of the SSDs for the models based on IM1.2 
( 4 75 5 38   ) and IM2.2 ( 4 11 4 18   ) were significantly less than those of the other 13 
models. We can see that that the IM1.2 and IM2.2 models were significantly better than the 
models based on the other 13 models ( 0 001 0 048p    ), but they were not significantly 
different each other (p=0.590). The control model was significantly worse than those based 
on all other models ( 0 001 0 020p    ) except for the 2 models (IM3.1 and IM3.2: p =0.106). 
4.7 What adherence assessment method (questionnaire vs MEMS) is best? 
Further, we compared the model fittings with all possible combinations of IC50 and the four 
determinants of adherence (A, M, M1.2 and M2.2). The mean of SSD for all the 10 models is 
plotted in Figure 4, and sign test p ─values from pairwise comparisons are reported in Table 
4. The results indicate that (i) the control model was significantly worse than those based on 
all other 9 models (p ≤0.001~0.007); (ii) the models IM1.2 and IM2.2 were significantly better 
than the other eight models (p≤0.001  0.048); (iii) the models I, A, M, M1.2, M2.2, IA and IM 
do not provide significantly different results (p=0.048  0.858) except for two marginally 
significant results. In particular, the models IA and IM are not better than the model I 
(p=0.209, 0.590), and the models IM1.2 and IM2.2 are significantly better than the models I, 
M1.2 and M2.2 (p=0.007  0.048). Overall, adherence assessed by an optimal summary 
MEMS metric with the confounding resistance factor combinations (IM1.2 and IM2.2) was a 
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better predictor of virologic response than adherence assessed by questionnaires, MEMS 
alone or two-factor combinations. 
 
Fig. 4. Comparison of SSDs for the models from 9 different determinants of adherence 
and/or drug resistance as well as the control model 
 
 Models Control I A M M1.2 M2.2 IA IM IM1.2 IM2.2 
p 
I <0.001          
A 0.007 0.106         
M 0.007 0.106 0.858        
M1.2 <0.001 0.106 0.590 0.858       
M2.2 <0.001 0.209 0.858 0.858 0.369      
IA <0.001 0.209 0.209 0.590 0.209 0.590     
IM <0.001 0.590 0.209 0.048 0.048 0.209 0.106    
IM1.2 <0.001 0.048 0.002 0.002 0.020 0.048 0.048 0.026   
IM2.2 <0.001 0.048 0.002 0.002 0.007 0.048 0.007 0.020 0.590  
   SSD Mean 11.30 6.09 6.68 6.69 6.68 6.45 6.06 5.27 4.75 4.11 
 ±SD 9.28 6.84 6.02 6.87 6.79 6.33 5.66 5.52 5.38 4.18 
Table 4. Pairwise comparisons of sum of squared deviations (SSD) from individual subjects 
for 10 models. The p-values were obtained using the sign test. 
5. Conclusion and discussion 
Several studies investigated the association between virologic responses and adherence 
assessed by MEMS data only without considering other confounding factors such as drug 
resistance using standard modeling methods including Poisson regression (Knafl et al., 
2004), logistic regression (Vrijens et al., 2005) and linear mixed-effects model (Liu et al., 
2007). In this article, we developed a mechanism-based nonlinear time-varying differential 
equation model for long-term dynamics to (i) establish the relationship of virologic response 
(viral load trajectory) with drug adherence and drug resistance, (ii) to describe both 
suppression and resurgence of virus, (iii) to directly incorporate observed drug adherence 
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and susceptibility into a function of treatment efficacy and (iv) to use a hierarchical Bayesian 
mixed-effects modeling approach that can not only combine prior information with current 
clinical data for estimating dynamic parameters, but also characterize inter-subject 
variability. Our modeling approach allows us to estimate time-varying antiretroviral 
efficacy during the entire course of a treatment regimen by incorporating the information of 
drug exposure and drug susceptibility. Thus, the results of estimated dynamic parameters 
based on this model should be more reliable and reasonable to interpret long-term HIV 
dynamics. Our models are simplified with the main goals of retaining crucial features of 
HIV dynamics and, at the same time, guaranteeing their applicability to typical clinical data, 
in particular, long-term viral load measurements.  
We employed the proposed mechanism-based dynamic model to assess how to efficiently 
use adherence rates based on questionnaires and MEMS dosing events to predict virologic 
response. In particular, we intended to address the questions (i) how to summarize the 
MEMS adherence data for efficient prediction of virologic response, and (ii) which 
adherence assessment method, questionnaire or MEMS, is a more efficient predictor of 
virologic response after accounting for potential confounding factors such as drug resistance 
between subjects.  
For the MEMS data, we found that the best summary metric for prediction of virologic 
response in terms of model fitting residuals (prediction error) is the adherence rate determined 
from MEMS dosing events averaged over a 2 week assessment interval, 1 week or 2 weeks 
prior to the next measured RNA observation (denoted by IM1.2 or IM2.2). The model fitting 
residuals from both models (IM2.2 and IM1.2) are significantly smaller than any other 13 
models (p≤0.001  0.048), but they were not significantly different each other (p=0.590).  
The model which used all available MEMS data between study visits to determine the 
adherence rate (the standard analysis) did not perform significantly better in terms of 
prediction of virologic response compared to the model with questionnaire adherence data 
(p=0.106).  
We also compared the model fittings with all possible combinations of IC50 and the four 
determinants of adherence data (see Fig. 4). The results indicate that (i) the control model 
was significantly worse than those based on all other 9 models (p≤0.001  0.007); (ii) the 
models IM1.2 and IM2.2 were significantly better than the eight other models 
(p≤0.001  0.048); (iii) the models I, A, M, M1.2, M2.2, IA and IM do not provide significantly 
different results (p=0.048  0.858) except for two marginally significant results. In particular, 
the models IA and IM did not improve upon the model I, which indicates that adherence 
measured by questionnaire and MEMS dosing events averaged over study visit interval did 
not provide any additional information to drug susceptibility in predicting virologic 
response. However, the models IM1.2 and IM2.2 did outperform the models I, M1.2 and 
M2.2, which indicates that the combination of drug susceptibility and adherence assessed 
over 2 week interval measured from 1 or 2 weeks prior to a RNA measurement provided 
significant additional information compared to either drug susceptibility or adherence alone 
in predicting virologic response.  
Although the analysis presented here used a simplified model, which appeared to perform 
well in capturing and explaining the observed patterns, and characterizing the biological 
mechanisms of HIV infection under relatively complex clinical situations, some limitations 
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exist for the proposed modeling method. Firstly, our model is a simplified model and there are 
many possible variations (Perelson and Nelson, 1999; Nowak and May, 2000; Callaway and 
Perelson, 2002). We did not separately consider the compartments of short-lived productively 
infected cells, long-lived and latently infected cells.(Perelson et al., 1997). Instead we examined 
a pooled productively infected cell population. The virus compartment was not further 
decomposed into infectious virions and non-infectious virions as in the paper by Perelson et 
al. (1996). Thus, different mechanisms of RTI and PI drug effects were not modeled. In fact, 
we only considered PI drug effects in the drug efficacy model (3) since the RTI drugs have a 
different adherence-resistance relationship. Further studies will be conducted in considering 
both PI and RTI drug effects in the models. Secondly, the availability of IC50 data was 
limited to baseline and failure time, as is typical in clinical trials. Thus, we extrapolated the 
IC50 data linearly to the whole treatment period in our modeling. The linear extrapolation is 
the best approximation that we can get from the sparse IC50 data (Wu et al., 2005). The linear 
assumption might have some influence on the estimation results since the IC50 might have 
jumped to a higher level earlier before the failure time when we obtained the sample for drug 
resistance test. However, we expect that this assumption had little effect on the prediction of 
virologic response since we had relatively frequent monitoring (monthly in the later stage) of 
virologic failure in this study. Thirdly, a more complete model of antiretroviral treatment 
efficacy would ideally also consider the time-varying function of concentrations of drug in 
plasma (Huang et al., 2003). Unfortunately, the limited availability of drug concentration data 
prohibited our inclusion of PK parameters in our model. Lastly, as measurements of adherence 
may not reflect actual adherence profiles for individual patients, the data quality would affect 
our estimation results for viral dynamic parameters. For example, adherence data measured 
by questionnaires may not be accurate. More accurate measurements of the MEMS adherence 
data were used in this paper and it was found that the MEMS adherence data can provide a 
better prediction of virologic response compared with the questionnaire adherence data, when 
the MEMS data are summarized in an appropriate way. Further studies on these issues are 
definitely needed. Nevertheless, these limitations would not offset the major findings from our 
modeling approach, although further improvement may be warranted.  
In summary, MEMS adherence data may not be correlated better to virologic response 
compared to questionnaire adherence data unless the MEMS cap data are summarized in an 
appropriate way where adherence was assessed over 2 week interval measured from 1 or 2 
weeks prior to a RNA measurement in our case. Our study also shows that the mechanism-
based dynamic model is powerful and effective to establish a relationship of antiviral 
response with drug exposure and drug susceptibility. 
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